Review of the 90th annual meeting of the British Association of Dermatologists, 6-8 July 2010, Manchester, U.K.

British Journal of Dermatology

Volumn 164, Issue 4, 2011, Pages 712-719

  Prasad Hunasehally, R Y ^a   Anstey, Alex ^b  

^a PRINCESS OF WALES HOSPITAL   (United Kingdom)

^b ROYAL GWENT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMELANOTIDE;

CONFERENCE PAPER; CONTACT DERMATITIS; DERMATOLOGY; HEALTH CARE DELIVERY; HUMAN; MEDICAL EDUCATION; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SOCIETY; MEDICAL SPECIALIST; PEDIATRICS; PHOTODERMATOLOGY; PRIORITY JOURNAL; SKIN CANCER; SKIN DISEASE; SKIN SURGERY; SOLAR URTICARIA;

DELIVERY OF HEALTH CARE; DERMATITIS, CONTACT; DERMATOLOGY; GREAT BRITAIN; HUMANS; PSORIASIS; SKIN NEOPLASMS;

EID: 79953699346     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10294.x     Document Type: Conference Paper

References (71)

1. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008; 59:524-9.
2. Lacouture ME, Lai SE. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 2006; 155:852-4. (Pubitemid 44352579)
3. Prey S, Paul C, Bronsard V et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2):23-30.
4. Goulding JMR, Price CL, Defty CL et al. Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need and a chance to intervene. Br J Dermatol 2010; 163 (Suppl. 1):6 (Abstract).
5. National Institute for Health and Clinical Excellence. Etanercept and Efalizumab for the Treatment of Adults with Psoriasis. [TA103]. London: National Institute for Health and Clinical Excellence, 2006.
6. National Institute for Health and Clinical Excellence. Adalimumab for the Treatment of Adults with Psoriasis. [TA146]. London: National Institute for Health and Clinical Excellence, 2008.
7. National Institute for Health and Clinical Excellence. Infliximab for the Treatment of Adults with Psoriasis. [TA134]. London: National Institute for Health and Clinical Excellence, 2008.
8. National Institute for Health and Clinical Excellence. Ustekinumab for the Treatment of Adults with Moderate to Severe Psoriasis. [TA180]. London: National Institute for Health and Clinical Excellence, 2009.
9. Smith CH, Anstey AV, Barker JNWN et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161:987-1019.
10. Woolf R, Robertson K, Smith CH, Barker JNWN. A 'real world' observational study of adalimumab in patients with moderate to severe psoriasis who have failed on etanercept therapy: a retrospective case cohort study. Br J Dermatol 2010; 163 (Suppl. 1):46-7 (Abstract).
11. Gordon K, Leonardi C, Griffiths CEM et al. Ustekinumab safety update: cumulative experience from longer-term follow-up of patients treated in the ustekinumab psoriasis clinical development programme. Br J Dermatol 2010; 163 (Suppl. 1):49-50 (Abstract).
12. Ryan C, Collins P, Kirby B, Rogers S. Clinical and genetic predictors of treatment response to narrowband ultraviolet B radiation for chronic plaque psoriasis. Br J Dermatol 2010; 163 (Suppl. 1):8 (Abstract).
13. Wahie S, Goodfield MJD, Carmichael AJ et al. Response to hydroxychloroquine in patients with discoid lupus erythematosus. Br J Dermatol 2010; 163 (Suppl. 1):9 (Abstract).
14. Goujon C, Bérard F, Dahel K et al. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006; 16:155-8.
15. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 2007; 156:346-51. (Pubitemid 46095964)
16. Lyakhovitsky A, Barzilai A, Heyman R et al. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol 2010; 24:43-9.
17. Meggitt SJ, Smith C, Petrof G, Reynolds NJ. A retrospective study of methotrexate for moderate-to-severe atopic eczema. Br J Dermatol 2010; 163 (Suppl. 1):4 (Abstract).
18. National Institute for Health and Clinical Excellence. Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis after the Failure of a TNF Inhibitor. [TA195]. London: National Institute for Health and Clinical Excellence, 2010.
19. Schmidt E, Hunzelmann N, Zillikens D et al. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006; 31:503-8. (Pubitemid 43806580)
20. Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann NY Acad Sci 2009; 1173:683-91.
21. Martyn-Simmons CL, Saha M, Black MM, Groves RW. A case series of 16 patients treated with rituximab for refractory immunobullous disease. Br J Dermatol 2010; 163 (Suppl. 1):5-6 (Abstract).
22. Ayoub N, Charuel JL, Diemert MC et al. Antineutrophil cytoplasmic antibodies of IgA class in neutrophilic dermatoses with emphasis on erythema elevatum diutinum. Arch Dermatol 2004; 140:931-6. (Pubitemid 39062643)
23. Shimizu S, Nakamura Y, Togawa Y et al. Erythema elevatum diutinum with primary Sjögren syndrome associated with IgA antineutrophil cytoplasmic antibody. Br J Dermatol 2008; 159:733-5.
24. Simpson R, Crichlow SM, Alexandroff AB, Harman KE. A case series of three patients with erythema elevatum diutinum in association with paraproteinaemia and IgA antineutrophil cytoplasmic antibodies. Br J Dermatol 2010; 163 (Suppl. 1):27 (Abstract).
25. Simpson R, Alvaro SJ, Morgan M et al. IgA from two patients with erythema elevatum diutinum associated with IgA antineutrophil cytoplasmic antibody stimulates superoxide production and degranulation of neutrophils in vitro. Br J Dermatol 2010; 163 (Suppl. 1):9-10 (Abstract).
26. Rajpara S, Varma S, Perks G, Perkins W. Mohs micrographic surgery for dermatofibrosarcoma protuberans. Br J Dermatol 2010; 163 (Suppl. 1):108-9 (Abstract).
27. Tan WP, McKenna J, Robson A, Mallipeddi R. Mohs micrographic surgery for dermatofibrosarcoma protuberans: experience in a large regional centre. Br J Dermatol 2010; 163 (Suppl. 1):110 (Abstract).
28. Hussain W, Salmon P, Gleeson C, Mortimer N. Collapse during scalp tumour extirpation: a cautionary tale for the Mohs micrographic surgeon. Br J Dermatol 2010; 163 (Suppl. 1):104 (Abstract).
29. Goldman G, Altmayer S, Sambandan P, Cook J. Development of cerebral air emboli during Mohs micrographic surgery. Dermatol Surg 2009; 35:1414-21.
30. Elder D, Xu X. The approach to the patient with a difficult melanocytic lesion. Pathology 2004; 36:428-34. (Pubitemid 39273986)
31. Al-Rawi H, Husain A, Lawrence CM. Melanocytic lesions of unknown malignant potential: features and outcome in 35 patients. Br J Dermatol 2010; 163 (Suppl. 1):101-2 (Abstract).
32. Rao NG. Review of the role of radiation therapy in the management of Merkel cell carcinoma. Curr Probl Cancer 2010; 34:108-17.
33. Chetty NC, Igali L, Moncrieff M, Garioch J. Management and outcomes of 28 cases of Merkel cell carcinoma treated in our centre, 2003-2008. Br J Dermatol 2010; 163 (Suppl. 1):55 (Abstract).
34. Benton EC, Crichton S, Agar NS et al. Cutaneous Lymphoma International Prognostic Index (CLIPI). Br J Dermatol 2010; 163 (Suppl. 1):11 (Abstract).
35. Benton EC, Robson AM, Wain EM. Hypopigmented mycosis fungoides: a study of the clinicopathological, immunophenotypic and prognostic features. Br J Dermatol 2010; 163 (Suppl. 1):6-7 (Abstract).
36. Pring A, Verne J, de Berker DAR. The incidence of second primary skin cancer in an English region. Br J Dermatol 2010; 163 (Suppl. 1):7 (Abstract).
37. Fogo A, Bashir S. Audit: infection rates following dermatological surgery. Br J Dermatol 2010; 163 (Suppl. 1):111-12 (Abstract).
38. Odunsi D, Morris-Jones R. Simple effective keloid surgery within the dermatology department. Br J Dermatol 2010; 163 (Suppl. 1):45-6 (Abstract).
39. Proudfoot LE, Cunningham M, Higgins EM, Morris-Jones R. Oral corticosteroids are not required for the successful management of kerions. Br J Dermatol 2010; 163 (Suppl. 1):118 (Abstract).
40. Paller AS, Siegfried EC, Langley RG et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358:241-51.
41. Cheng S, Murphy R. The use of etanercept in children and adolescents with moderate-to-severe plaque psoriasis: a report of three successful cases. Br J Dermatol 2010; 163 (Suppl. 1):120 (Abstract).
42. Kelsell DP, Norgett EE, Unsworth H et al. Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet 2005; 76:794-803. (Pubitemid 40563101)
43. Rajpopat S, O'Toole E, Kelsell D. Novel ABCA12 mutations in harlequin ichthyosis and a review of clinical outcomes. Br J Dermatol 2010; 163 (Suppl. 1):119 (Abstract).
44. Lai-Cheong J, Techanukul T, Parsons M et al. Revertant mosaicism in Kindler syndrome resulting from FERMT1 transcriptional gene correction. Br J Dermatol 2010; 163 (Suppl. 1):3-4 (Abstract).
45. Hunasehally RYP, Hughes TM, Stone NM. Nine years' experience of patch testing to investigate footwear allergic contact dermatitis: can the distribution of rash help predict the cause or the allergens involved? Br J Dermatol 2010; 163 (Suppl. 1):79 (Abstract).
46. Nardelli A, Tavierne M, Drieghe J et al. The relation between the localisation of foot dermatitis and the causative allergens in shoes: a 13 year retrospective study. Contact Dermatitis 2005; 53:201-6. (Pubitemid 41499693)
47. McAleer MA, Bourke J. Patch testing for perineal dermatitis: 13 years' experience. Br J Dermatol 2010; 163 (Suppl. 1):81-2 (Abstract).
48. Al-Niaimi F, Williams J, Pavey C. Retrospective review of 282 patients who were patch tested for vulval symptoms. Br J Dermatol 2010; 163 (Suppl. 1):86 (Abstract).
49. González-Pérez R, Trébol I, García-Río I et al. Allergic contact dermatitis from methylene-bis-benzotriazolyl tetramethylbutyl phenol (Tinasorb M®). Contact Dermatitis 2007; 56:121. (Pubitemid 46143964)
50. O'Connell M, Wilkinson M. Allergic contact dermatitis to methylene- bis-benzotriazolyl tetramethylbutyl phenol. Br J Dermatol 2010; 163 (Suppl. 1):79-80 (Abstract).
51. Khorasgania GM, Johnston G. Photoallergic contact dermatitis to isoamyl methoxycinnamate in an organic sunscreen. Br J Dermatol 2010; 163 (Suppl. 1):86 (Abstract).
52. Darvay A, White IR, Rycroft RJ et al. Photoallergic contact dermatitis is uncommon. Br J Dermatol 2001; 145:597-601.
53. Schauder S, Ippen H. Contact and photocontact sensitivity to sunscreens. Review of a 15-year experience and of the literature. Contact Dermatitis 1997; 37:221-32.
54. Kai A, Grattan C, White IR, White JML. The role of patch testing in chronic urticaria. Br J Dermatol 2010; 163 (Suppl. 1):84-5 (Abstract).
55. Guerra L, Rogkakou A, Massacane P et al. Role of contact sensitisation in chronic urticaria. J Am Acad Dermatol 2007; 56:88-90. (Pubitemid 44969300)
56. Haylett AK, Nie Z, Brownrigg M et al. The a-melanocyte stimulating hormone analogue afamelanotide conveys photoprotection in solar urticaria. Br J Dermatol 2010; 163 (Suppl. 1):132 (Abstract).
57. Shareef MS, Dawe RS. Bath psoralen plus ultraviolet A for hidradenitis suppurativa: a review of 13 patients. Br J Dermatol 2010; 163 (Suppl. 1):135-6 (Abstract).
58. Schofield J, Fleming D, Grindlay D, Williams H. Skin conditions are the commonest new reason people present to general practitioners in England and Wales: implications for education and training. Br J Dermatol 2010; 163 (Suppl. 1):1 (Abstract).
59. Zafiriu B, Yesudian PD. Does undergraduate dermatology education affect junior doctors' diagnostic and therapeutic skills? Br J Dermatol 2010; 163 (Suppl. 1):36-7 (Abstract).
60. Sherley-Dale AC, Jones C, Bakkour W et al. The role of the dermatologist in reducing the length of inpatient stays: an audit demonstrating dispensing of topical agents by the dermatology team results in expedient treatment. Br J Dermatol 2010; 163 (Suppl. 1):1-2 (Abstract).
61. National Institute for Health and Clinical Excellence. Improving Outcomes for People with Skin Tumours including Melanoma. London: National Institute for Health and Clinical Excellence, 2006.
62. Ali G, Garioch J, Tan E et al. Management of cutaneous melanoma in primary care in the East of England. Br J Dermatol 2010; 163 (Suppl. 1):55 (Abstract).
63. Dewan P, Panagou E, Kajen S et al. Are NICE skin cancer guidelines being followed in primary care? A re-audit to review changes in an inner city setting. Br J Dermatol 2010; 163 (Suppl. 1):65 (Abstract).
64. Alsharqi A, Wilson N, De Mozzi P. Basal cell carcinomas excision margins: primary vs. secondary care. Br J Dermatol 2010; 163 (Suppl. 1):101 (Abstract).
65. Khorasgani MG, Payne S, Khorshid M. Dermatological surgery in the community: are the guidelines being followed? Br J Dermatol 2010; 163 (Suppl. 1):115 (Abstract).
66. National Institute for Health and Clinical Excellence. Improving Outcomes for People with Skin Tumours including Melanoma (update): The Management of Low-risk Basal Cell Carcinomas in the Community. London: National Institute for Health and Clinical Excellence, 2010.
67. Health Protection Agency. Guidance on the diagnosis and management of PVL-associated Staphylococcus aureus infections (PVL-SA) in England. 2008. Available at: http://www.hpa.org.uk/web/HPAwebFile/HPAweb-C/1218699411960 (last accessed 21 February 2011).
68. Fogo A, Wade J, Morris-Jones R, Hay R. Panton-Valentine leucocidin-positive Staphylococus aureus cause recalcitrant infections in dermatology patients. Br J Dermatol 2010; 163 (Suppl. 1):8 (Abstract).
69. Orpin S. Sir Archibald Gray 1880-1967: founding father of the British Association of Dermatologists. Br J Dermatol 2010; 163 (Suppl. 1):71 (Abstract).
70. Paul L. Niels Ryberg Finsen: the only dermatologist to be awarded the Nobel Prize for medicine. Br J Dermatol 2010; 163 (Suppl. 1):73 (Abstract).
71. Sherley-Dale A. A. Bernard Ackerman (1936-2008): a Princeton tiger finally rests. Br J Dermatol 2010; 163 (Suppl. 1):75-6 (Abstract).